Abingdon Health PLC
LSE:ABDX

Watchlist Manager
Abingdon Health PLC Logo
Abingdon Health PLC
LSE:ABDX
Watchlist
Price: 8.4 GBX 5%
Market Cap: 16.3m GBX
Have any thoughts about
Abingdon Health PLC?
Write Note

Abingdon Health PLC
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Abingdon Health PLC
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Abingdon Health PLC
LSE:ABDX
Operating Expenses
-ÂŁ5.7m
CAGR 3-Years
-11%
CAGR 5-Years
2%
CAGR 10-Years
N/A
ConvaTec Group PLC
LSE:CTEC
Operating Expenses
-$935.4m
CAGR 3-Years
-5%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Tristel PLC
LSE:TSTL
Operating Expenses
-ÂŁ26.4m
CAGR 3-Years
-11%
CAGR 5-Years
-13%
CAGR 10-Years
-14%
Inspecs Group PLC
LSE:SPEC
Operating Expenses
-ÂŁ100.7m
CAGR 3-Years
-63%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Advanced Medical Solutions Group PLC
LSE:AMS
Operating Expenses
-ÂŁ59m
CAGR 3-Years
-20%
CAGR 5-Years
-11%
CAGR 10-Years
-11%
Rua Life Sciences PLC
LSE:RUA
Operating Expenses
-ÂŁ3.7m
CAGR 3-Years
-10%
CAGR 5-Years
-28%
CAGR 10-Years
N/A
No Stocks Found

Abingdon Health PLC
Glance View

Market Cap
16.3m GBX
Industry
Health Care

Abingdon Health Plc develops, manufactures and commercializes immunoassay tests and reader systems. The company is headquartered in York, North Yorkshire and currently employs 151 full-time employees. The company went IPO on 2020-12-15. The firm operates through three segments: Contract Development, Contract Manufacturing and Product Sales. The Contract Development segment comprises development work for third parties and is recognized over time based on a proportion of completion. The Contract Manufacturing segment comprises contract development and manufacturing activities. The Product Sales segment comprises the sale of ABC-19, pocket diagnostic products, progressive rod cone degeneration (PCRD) tests and antibodies for research use. Its products also include Seralite, which includes Free Light Chain (FLC) Serum. The Company’s geographical market include the United Kingdom, the United States/Canada, rest of world (ROW).

ABDX Intrinsic Value
11.84 GBX
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Abingdon Health PLC's Operating Expenses?
Operating Expenses
-5.7m GBP

Based on the financial report for Jun 30, 2023, Abingdon Health PLC's Operating Expenses amounts to -5.7m GBP.

What is Abingdon Health PLC's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
2%

Over the last year, the Operating Expenses growth was 36%. The average annual Operating Expenses growth rates for Abingdon Health PLC have been -11% over the past three years , 2% over the past five years .

Back to Top